Special Issue

Advances in Targeted Delivery of Nanomedicines, 2nd Edition

Message from the Guest Editor

Targeted and specific drug delivery has been especially challenging because of simultaneous pathophysiological mechanistic processes happening in vitro. For example, recording cancer-signaling pathophysiological processes would provide valuable information for the development of impactful therapeutics with high precision, which can provide therapy in challenging in-cellular environments plagued by drug resistance. This opens up new avenues for broadening existing nanoscience research by developing novel nanomedicines with a high potential for clinical translation, as the superior endurance of nanomaterials (due to their chemical and photophysical attributes) provides an additional edge over conventional therapeutics, which offers exciting prospects.

Guest Editor

Dr. Sreejesh Sreedharan Human Sciences Research Centre, University of Derby, Derby DE221GB, UK

Deadline for manuscript submissions

30 April 2026



Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/258525

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/ molecules





Molecules

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 29th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

